Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/50

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/004622ANTIBODY AGAINST SARS-COV-2, METHOD FOR DETECTING SARS-COV-2 USING ANTIBODY AND KIT CONTAINING ANTIBODY
WO 06.01.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/JP2021/024267 Applicant PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY Inventor RYO, Akihide
The present invention addresses the problem of providing a means for detecting a constituting protein of nucleocapsid derived from SARS-CoV-2. This problem has been solved by providing an antibody binding to a constituting protein of nucleocapsid derived from SARS-CoV-2 or a fragment of the antibody, a method for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid with the use of the antibody or a fragment thereof, a kit for detecting a constituting protein of the SARS-CoV-2-derived nucleocapsid, said kit containing the antibody or a fragment thereof, etc.
2.WO/2022/000845RECOMBINANT PROTEIN VACCINE FOR PREVENTING SARS-COV-2 AND PREPARATION METHOD THEREFOR
WO 06.01.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2020/119701 Applicant JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION (PUBLIC HEALTH RESEARCH INSTITUTE OF JIANGSU PROVINCE) Inventor ZHU, Fengcai
A target amino acid sequence of a SARS-CoV-2 recombinant protein vaccine, a target gene sequence of the recombinant protein vaccine, a eukaryotic cell expression vector containing the target gene sequence, a cell expressing the target amino acid sequence, and the recombinant protein vaccine having the target amino acid sequence as an antigen. The recombinant protein vaccine can effectively induce a body to produce cellular immunity and humoral immunity, can be quickly prepared, and is suitable for the prevention of novel coronavirus.
3.113832168mRNA疫苗及其制备方法和应用
CN 24.12.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202110933810.2 Applicant 北京科兴中维生物技术有限公司 Inventor 高强
本文公开了一种分离的mRNA及其制备方法和应用,所述mRNA编码重组表面刺突(S)蛋白,所述重组S蛋白来源于严重急性呼吸系统综合症冠状病毒(SARS‑CoV‑2),且包含在N末端结构域中的缺失和弗林酶切位点结构域的缺失。
4.WO/2021/254473IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
WO 23.12.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CN2021/100826 Applicant MEDIGEN VACCINE BIOLOGICS CORPORATION Inventor KUO, Tsun-Yung
Provided an immunogenic composition against severe acute respiratory syndrome coronavirus (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
5.WO/2021/257888TYPE 2 CYTOKINES AS PREDICTORS OF DISEASE SEVERITY AND/OR AS THERAPEUTIC TARGETS FOR COVID-19
WO 23.12.2021
Int.Class A61K 38/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
Appl.No PCT/US2021/037912 Applicant UNIVERSITY OF VIRGINIA PATENT FOUNDATION Inventor PETRI, William, A. Jr.
Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, is described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, treatment of a subject with a therapeutic agent that neutralizes interleukin 13 (IL-13) can result in reduced risk for mechanical ventilation in the subject. Also described are methods of predicting risk of mechanical ventilation in subjects with COVID-19.
6.WO/2021/253962NOVEL CORONAVIRUS VACCINE CANDIDATE STRAIN USING RECOMBINANT NEWCASTLE DISEASE VIRUS AS VECTOR, CONSTRUCTION METHOD THEREFOR, AND APPLICATION THEREOF
WO 23.12.2021
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2021/087976 Applicant ZHEJIANG DIFFERENCE BIOLOGICAL TECHNOLOGY CO., LTD Inventor SONG, Jiasheng
Provided are a novel coronavirus vaccine candidate strain using a recombinant Newcastle disease virus as a vector, a construction method therefor, and an application thereof, pertaining to the technical field of genetically-engineered vaccines. The vaccine candidate strain uses a Newcastle disease virus LaSota strain as a vector. A novel coronavirus S gene with a mutation (C3756T, BamHI site removed) is inserted between the P gene and the M gene of the Newcastle disease virus LaSota strain. The nucleotide sequence of the mutant novel coronavirus S gene is as shown in SEQ ID NO. 1.
7.WO/2021/254327ENVELOPE REPLACEMENT-TYPE VIRAL VECTOR VACCINE AND CONSTRUCTION METHOD THEREFOR
WO 23.12.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2021/100107 Applicant FANTASIA BIOPHARMA (ZHEJIANG) CO. LTD Inventor QIN, Frank XiaoFeng
Disclosed is an envelope replacement-type viral vector vaccine. The Vesicular stomatitis virus VSV is used as a vector, and the GP gene in the VSV virus genome is replaced with a truncated segment of a spike protein S gene of a coronavirus or a fused ECD-CA of an extracellular segment and a GP-C segment of the spike protein S gene of the coronavirus. The truncated segment of the spike protein S gene is selected from genes with some amino acid deletions at the C-terminus, and the ECD-CA is a gene formed by means of fusing the extracellular segment of the spike protein S gene of the coronavirus with the transmembrane and intracellular segment genes of the VSV viral envelope protein. Also disclosed is a method for constructing the envelope replacement-type viral vector vaccine.
8.WO/2021/257781COMPOSITIONS AND METHODS FOR TREATING COVID-19
WO 23.12.2021
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/US2021/037747 Applicant VAST SEA BIOTECHNOLOGY, INC. Inventor LAI, Norman Zhennan
This disclosure is directed to inhibitory oligonucleotides, inhibitory peptides, compositions and methods for preventing or treating Coronavirus disease 2019 (COVID-19). In one aspect, the disclosure is directed to compositions that comprise inhibitory oligonucleotides against one or more SARS-CoV-2 virus genes. In another aspect, the disclosure is directed to compositions that comprise inhibitory peptides that inhibit SARS-COV-2 entry into cells. Another aspect of the disclosure is directed to gene therapy methods for treating COVID-19, and vectors for carrying out the same. Finally, the disclosure provides nutritional supplements to support human immunity and prevent or inhibit viral infections.
9.WO/2021/255787SARS-COV-2 DETECTION PRIMER SET, SARS-COV-2 TESTING METHOD, AND SARS-COV-2 TEST REAGENT AND TEST KIT
WO 23.12.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/JP2020/023401 Applicant NAGASAKI UNIVERSITY Inventor YASUDA, Jiro
The present invention provides a technology that enables rapid detection of SARS-CoV-2 by specifically amplifying nucleic acids originating from SARS-CoV-2. More specifically, the present invention provides a technology related to a primer set and the use of said primer set, the primer set being a SARS-CoV-2 detection primer set that contains a plurality of LAMP primers targeting at least one open reading frame (ORF) region in the SARS-CoV-2 genome, wherein the at least one ORF region is selected from the group consisting of Orf1b, OrfM, OrfN, and OrfS.
10.113817029一种新型冠状病毒S-RBD三聚体蛋白疫苗、其制备方法和应用
CN 21.12.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202110348881.6 Applicant 国药中生生物技术研究院有限公司 Inventor 李启明
本发明公开了一种新型冠状病毒S‑RBD三聚体蛋白,所述三聚体蛋白由三聚体形式的新型冠状病毒S蛋白RBD区第319~537位氨基酸片段构成。本发明制备的疫苗以S‑RBD三聚体蛋白为抗原,辅以佐剂后,免疫机体,可产生针对新型冠状病毒的高滴度保护性中和抗体,可以用于治疗和/或预防新型冠状病毒(SARS‑CoV‑2)感染和/或新型冠状病毒疾病。